Supraflex Cruz evidence presented at TCT 2025
In November 2025, EUKON shared an update from Sahajanand Medical…
IVUS + NIRS: The PROSPECT II Study Published on The Lancet
11 March 2021
The PROSPECT II Study has been published in the current issue of The Lancet.
Study findings show that combined #NIRS and #IVUS detects angiographically non-obstructive lesions with a high lipid content and large plaque burden that are at increased risk for future adverse cardiac outcomes.
Click The PROSPECT II Study to read more
Latest News:
LaaGuarder: first European clinical use announced by EUKON
In January 2026, EUKON announced the first clinical use in…
Supraflex Cruz NEVO now available to Italian cath labs
EUKON announced the availability of Supraflex Cruz NEVO to Italian…